Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response 

Results, presented simultaneously in oral presentation at ASCO…Read More

You might also be interested in reading F1 Sponsorship Trends, Executive Coaching, New Name in CFD Volumes Ranking.